In particular, we detected only a small number of patients with SLS positivity in the TC or TP, particularly among those with aggressive disease (i.e., T3–T4 subgroup), highlighting the need for additional studies assessing the prognostic implications of LC3A expression patterns in larger cohorts of rectal cancer patients. Here, MAP1LC3A is linked to rectal cancer.